600085.SS
Latest Trade
25.71CNYChange
-0.10(-0.39%)Volume
2,761,491Today's Range
-
25.9452 Week Range
-
34.08As of on the Shanghai Stock Exchange ∙ Minimum 15 minute delay
Previous Close | 25.81 |
|---|---|
Open | 25.85 |
Volume | 2,761,491 |
3M AVG Volume | 86.09 |
Today's High | 25.94 |
Today's Low | 25.68 |
52 Week High | 34.08 |
52 Week Low | 25.49 |
Shares Out (MIL) | 1,371.47 |
Market Cap (MIL) | 35,397.65 |
Forward P/E | 30.36 |
Dividend (Yield %) | 2.19 |
Beijing Tongrentang's 9-Month Net Profit Up 0.04% Y/Y
Beijing Tongrentang's H1 Net Profit Up 3.3% Y/Y
Beijing Tongrentang Says 2018 Net Profit Up 11.5 Percent Y/Y
BEIJING TONGRENTANG CO., LTD is a China-based company principally engaged in the production and sales of traditional Chinese patent medicines. The Company’s main products consist of liuwei dihuang series, tongren dahuoluo series, tongren niuhuang qingxin series, angong niuhuang series and donkey-hide gelatin series. The Company distributes its products under the brand of Tongrentang. The Company is also involved in the operation of Tongrentang drug stores. The Company distributes its products in domestic market and to overseas markets.
Industry
Biotechnology & Drugs
Executive Leadership
Zhenkun Gao
Chairman of the Board
Zhimei Feng
Chief Accounting Officer, Director
Shubing Di
General Manager
Zetao Jia
Deputy General Manager, Secretary of the Board, Director
Qingquan Wang
Deputy General Manager
Price To Earnings (TTM) | 31.20 |
|---|---|
Price To Sales (TTM) | 2.59 |
Price To Book (MRQ) | 3.61 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 15.64 |
LT Debt To Equity (MRQ) | 12.43 |
Return on Investment (TTM) | 16.57 |
Return on Equity (TTM) | 8.47 |
Beijing Tongrentang Co Ltd: Chang Chun Eurasia Group Co Ltd: Dashang Co Ltd: Gemdale Corp
* Says its tech development unit received goods manufacture practice (GMP) certificate from Beijing Food and Drug Administration
Beijing Tongrentang Co Ltd * Says 9-month net profit up 8.1 percent y/y Source text in Chinese: http://bit.ly/2yVP5kp Further company coverage: (Reporting by Hong Kong newsroom)
* Says its unit received goods manufacture practice (GMP) certificate from Beijing Food and Drug Administration
* Says it adopted new accounting policy regarding subsidy, effective since June 12
* Says H1 net profit up 6.5 percent y/y at 599.8 million yuan ($90.55 million)
* Says Q1 net profit up 12.0 percent y/y at 293.9 million yuan ($42.63 million)
* Says it plans to pay cash 2.4 yuan per 10 shares as FY 2016 div payment
* Says 2016 net profit up 6.6 percent y/y at 933.2 million yuan ($135.73 million)
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.